首页> 中文期刊> 《齐齐哈尔医学院学报》 >益气养阴方联合化疗在中晚期非小细胞肺癌治疗中的应用

益气养阴方联合化疗在中晚期非小细胞肺癌治疗中的应用

         

摘要

目的:探讨益气养阴方联合化疗在中晚期非小细胞肺癌治疗中的应用效果。方法本组83例患者随机分为观察组(n=43)和对照组(n=40)。观察组采用益气养阴方联合化疗治疗,对照组单用化疗治疗。结果观察组总有效率(53.49%)显著高于对照组(30.00%),且具有显著性意义(P<0.05);观察组CD3+、CD4+、CD4+/CD8+显著高于对照组, CD8+显著低于对照组,且均具有显著性意义( P<0.05);观察组治疗后KPS评分提高患者显著多于对照组,且具有显著性意义(P<0.05);观察组血清CEA和CA125治疗后显著低于对照组,且均具有显著性意义( P<0.05)。结论益气养阴方联合化疗在中晚期非小细胞肺癌治疗中的应用效果显著。%Objective To investigate the application effect of Yiqiyangyin prescription combined with chemotherapy in treating advanced non-small cell lung cancer .Methods Total of 83 patients were randomly divided into observation group (n=43) and control group (n=40).Patients in observation group were treated with Yiqiyangyin prescription combined chemotherapy , while the patients in control group were treated with chemotherapy alone.Results The overall response rate of observation group (53.49%) was significantly higher than that of control group (30.00%), the difference was statistically significant (P<0.05).The concentration of CD3 +and CD4 +and the ratio of CD4+/CD8+of observation group significantly higher than that of control group, however, the concentration of CD8+of observation group was significantly lower than the control group , the differences were statistically significant ( P <0.05).After the treatment, KPS increasing patients in observation group significant excess than the control group , and serum CEA and CA 125 of the observation significantly lower than the control group (P <0.05).Conclusions Yiqiyangyin prescription combined with chemotherapy has significant effect in treating advanced non-small cell lung cancer .

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号